Evolus (NASDAQ:EOLS) Announces Quarterly Earnings Results

Evolus (NASDAQ:EOLS) posted its quarterly earnings results on Wednesday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.13), FiscalAI reports. The firm had revenue of $77.95 million during the quarter, compared to analyst estimates of $77.58 million.

Here are the key takeaways from Evolus’ conference call:

• Third-quarter revenue rose 13% to $78 million, including $70.1 million in toxin revenue and $7.9 million in HA revenue. Adjusted EBITDA was positive for the fourth consecutive quarter at $1.2 million; year-to-date adjusted EBITDA improved to $6.4 million from a loss of $16.5 million a year earlier.
• Evolus reaffirmed full-year revenue guidance of $330 million–$337 million and adjusted gross margin guidance of 67%–67.5%, while lowering its non-GAAP operating expense outlook to $210 million–$213 million. It also maintained its low- to mid-single-digit adjusted EBITDA margin outlook for 2026 and 2028 targets of $450 million–$500 million in revenue and 13%–15% adjusted EBITDA margins.
• Commercial traction broadened: the company added more than 500 purchasing accounts, bringing its cumulative customer base above 19,000, while more than 4,500 customers have purchased Evolysse. Evolus Rewards membership increased 23% year over year to more than 1.6 million, and the company said about 70% of existing patients return for repeat treatment.
• The company expects FDA approval of Evolysse Sculpt in the fourth quarter of 2026 and anticipates submitting the Lips PMA before year-end, with a launch expected in early 2028. Profhilo is a longer-term U.S. opportunity with approval anticipated around 2030; the hair-growth asset remains an early-stage option subject to human data.
• The FDA issued an untitled letter concerning a single Jeuveau social-media post. Management said the post was removed, the concern would be addressed, and the letter would not affect Jeuveau promotion or the business.

Evolus Stock Up 1.4%

NASDAQ:EOLS traded up $0.10 during trading hours on Wednesday, reaching $7.47. 830,278 shares of the stock were exchanged, compared to its average volume of 698,632. The business has a 50-day moving average of $7.89 and a two-hundred day moving average of $6.29. The company has a market capitalization of $493.39 million, a price-to-earnings ratio of -14.37 and a beta of 1.38. Evolus has a twelve month low of $3.86 and a twelve month high of $9.31.

Insider Activity

In related news, insider David Moatazedi sold 105,108 shares of Evolus stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total value of $950,176.32. Following the completion of the transaction, the insider directly owned 499,592 shares in the company, valued at approximately $4,516,311.68. This trade represents a 17.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 5.00% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on EOLS shares. Wall Street Zen raised Evolus from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evolus in a research report on Friday, September 11th. Finally, HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Evolus in a research note on Tuesday, August 25th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $14.50.

Evolus Company Profile

Evolus, Inc is a commercial-stage medical aesthetics company focused on developing and marketing products for physicians and other licensed aesthetic providers. The company’s business is centered on minimally invasive treatments intended to address facial lines, wrinkles and other visible signs of aging.

Evolus’ primary product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved by the U.S. Food and Drug Administration for the temporary improvement of moderate to severe glabellar lines, commonly known as “frown lines,” in adults.